RA DePINHO, LB FELDMAN, MD … - Annals of internal …, 1986 - Am Coll Physicians Monoclonal antibodies, potentially powerful diagnostic and therapeutic reagents, are having
a significant impact in basic and clinical research. Some persisting problems must be
solved, however, in order to realize the potential of this technology. We review the basic ... Cited by 18 - Related articles - All 3 versions
[CITATION] Oratz R. Liebes L, et al. Phase Ib trial of granulocyte-macrophage colony- …
C Wiseman, V Hammock, L Barton, V … - Journal of …, 1994 - journals.lww.com Advertisement. Journal of Immunotherapy. Wolters Kluwer Health Logo. All Issues. ... Cited by 3 - Related articles
RS Geha - Journal of Immunotherapy, 1984 - journals.lww.com Advertisement. Journal of Immunotherapy. Wolters Kluwer Health Logo. All Issues. ... Cited by 5 - Related articles - All 2 versions
KK Wong Jr, DL Sweet, D Variakojis - CA A Cancer Journal for … - interscience.wiley.com A 20-year-old man with previously treated lymphoblastic lymphoma, a known T-cell disorder,
developed progressive disease despite intensive combination chemotherapy with
doxorubicin, vincristine, and prednisone. He was subsequently treated with a 21-day ... Cited by 5 - Related articles - All 2 versions
[CITATION] Higher cytolytic efficiency of an IgG2A than of an IgGl monoclonal antibody with the …
R Levy - Journal of Clinical Oncology, 1987 - jco.ascopubs.org ANTIBODIES have the ability to distinguish - between different types of cells and to me- diate
the destruction of cells to which they bind. For this reason, it has long been hoped that anti- bodies
could be used to kill tumor cells more selectively than do the current cytotoxic ther- apies. ... Cited by 8 - Related articles - View as HTML - All 5 versions
